These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 15372852

  • 1. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (Part 2): Clinical experience in children.
    van Schayck CP, Donnell D.
    Int J Clin Pract; 2004 Aug; 58(8):786-94. PubMed ID: 15372852
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma.
    Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D.
    J Allergy Clin Immunol; 2000 Dec; 106(6):1209-26. PubMed ID: 11112914
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults.
    Van Schayck CP, Donnell D.
    Int J Clin Pract; 2004 Jul; 58(7):678-88. PubMed ID: 15311725
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol.
    Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM.
    Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of once or twice daily inhalation of extrafine HFA beclomethasone dipropionate in patients with mild to moderate asthma.
    Gillissen A, Richter A, Oster H, Criée CP.
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):233-41. PubMed ID: 18204133
    [Abstract] [Full Text] [Related]

  • 6. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children.
    Pedersen S, Warner J, Wahn U, Staab D, Le Bourgeois M, Van Essen-Zandvliet E, Arora S, Szefler SJ, Pediatric Study Group.
    Pediatrics; 2002 Jun; 109(6):e92. PubMed ID: 12042586
    [Abstract] [Full Text] [Related]

  • 7. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study.
    Barnes N, Price D, Colice G, Chisholm A, Dorinsky P, Hillyer EV, Burden A, Lee AJ, Martin RJ, Roche N, von Ziegenweidt J, Israel E.
    Clin Exp Allergy; 2011 Nov; 41(11):1521-32. PubMed ID: 21752116
    [Abstract] [Full Text] [Related]

  • 8. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma.
    Reichel W, Dahl R, Ringdal N, Zetterstrom O, van den Elshout FJ, Laitinen LA.
    Int J Clin Pract; 2001 Mar; 55(2):100-6. PubMed ID: 11321849
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices.
    Derom E, Pauwels RA.
    Clin Pharmacokinet; 2005 Mar; 44(8):815-36. PubMed ID: 16029067
    [Abstract] [Full Text] [Related]

  • 10. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose.
    Davies RJ, Stampone P, O'Connor BJ.
    Respir Med; 1998 Jun; 92 Suppl A():23-31. PubMed ID: 9850360
    [Abstract] [Full Text] [Related]

  • 11. Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children.
    Devadason SG, Huang T, Walker S, Troedson R, Le Souëf PN.
    Eur Respir J; 2003 Jun; 21(6):1007-11. PubMed ID: 12797496
    [Abstract] [Full Text] [Related]

  • 12. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open- label, randomized trial.
    Szefler SJ, Warner J, Staab D, Wahn U, Le Bourgeois M, van Essen-Zandvliet EE, Arora S, Pedersen S, Pediatric Study Group.
    J Allergy Clin Immunol; 2002 Jul; 110(1):45-50. PubMed ID: 12110818
    [Abstract] [Full Text] [Related]

  • 13. Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite).
    Bousquet J, Cantini L.
    Respir Med; 2002 Aug; 96 Suppl D():S17-27. PubMed ID: 12201078
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma.
    Farmer IS, Middle M, Savic J, Perri VL, Herdman MJ.
    Respir Med; 2000 Jan; 94(1):57-63. PubMed ID: 10714480
    [Abstract] [Full Text] [Related]

  • 15. Improvements in delivery with an extra fine beclomethasone aerosol.
    Davies R.
    Int J Clin Pract Suppl; 1998 Sep; 96():28-32. PubMed ID: 10344031
    [Abstract] [Full Text] [Related]

  • 16. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma.
    Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J.
    Chest; 1999 Feb; 115(2):343-51. PubMed ID: 10027430
    [Abstract] [Full Text] [Related]

  • 17. Short-term lower leg growth in 5- to 11-year-old asthmatic children using beclomethasone dipropionate inhalers with chlorofluorocarbon or hydrofluoroalkane propellants: a 9-week, open-label, randomized, crossover, noninferiority study.
    Wolthers OD, Walters EG.
    Clin Ther; 2011 Aug; 33(8):1069-76. PubMed ID: 21784529
    [Abstract] [Full Text] [Related]

  • 18. Modulite technology: pharmacodynamic and pharmacokinetic implications.
    Woodcock A, Acerbi D, Poli G.
    Respir Med; 2002 Aug; 96 Suppl D():S9-15. PubMed ID: 12201080
    [Abstract] [Full Text] [Related]

  • 19. A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness.
    Fardon TC, Burns P, Barnes ML, Lipworth BJ.
    Ann Allergy Asthma Immunol; 2006 Mar; 96(3):422-30. PubMed ID: 16597076
    [Abstract] [Full Text] [Related]

  • 20. Bioavailability of Beclometasone From Two HFA-BDP Formulations With a Spacer.
    Said AS, AbuRuz S, Chrystyn H.
    Respir Care; 2019 Oct; 64(10):1222-1230. PubMed ID: 31138731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.